Antengene announces new drug application for ATG-010 (selinexor) granted priority review by China's NMPA

23 February 2021 - Antengene today announced that China's National Medical Products Administration has granted priority review to the new drug ...

Read more →

The BCMA CAR-T co-developed by Innovent and IASO was granted breakthrough therapy designation by the NMPA for the treatment of relapsed/refractory multiple myeloma

22 February 2021 - Innovent Biologics today jointly announce that the Center for Drug Evaluation of China's National Medical Products Administration ...

Read more →

Junshi Biosciences announces acceptance by the NMPA of supplemental new drug application for toripalimab combined with chemotherapy for the first-line treatment of nasopharyngeal carcinoma

19 February 2021 - Third sNDA for toripalimab in China. ...

Read more →

Innovent and Lilly jointly announce the approval of Tyvyt (sintilimab) by China NMPA in combination with pemetrexed and platinum chemotherapy as first-line therapy for non-squamous non-small cell lung cancer

3 February 2021 - Innovent Biologics and Eli Lilly today jointly announced that the National Medical Products Administration of China has ...

Read more →

Bayer receives approval for Nubeqa in China for the treatment of men with non-metastatic castration-resistant prostate cancer

3 February 2021 - The Chinese National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide) for the treatment of patients with ...

Read more →

Astellas' Xospata (gilteritinib) receives conditional approval by China's National Medical Products Administration for relapsed or refractory acute myeloid leukaemia with a FLT3 mutation

3 February 2021 - Accelerated approval follows priority review designation and inclusion in overseas new drugs urgently needed in clinical settings. ...

Read more →

Forxiga approved in China for heart failure

4 February 2021 - Forxiga is the first SGLT2 inhibitor approved in China for heart failure with reduced ejection fraction in ...

Read more →

Symbicort Turbuhaler approved in China as an anti-inflammatory reliever in mild asthma

26 January 2021 - Symbicort Turbuhaler becomes the first dual-combination therapy approved in China for mild, moderate and severe asthma ...

Read more →

China National Medical Products Administration approves tislelizumab in combination with chemotherapy in first-line advanced squamous non-small cell lung cancer

13 January 2021 - BeiGene today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products ...

Read more →

Innovent announces NMPA acceptance of a supplemental new drug application for Tyvyt (sintilimab injection) in combination with Byvasda (bevacizumab injection) as first-line therapy in hepatocellular carcinoma

12 January 2021 - Innovent Biologics today announced that the National Medical Products Administration of China has accepted the supplemental ...

Read more →

Zai Lab announces inclusion of Zejula (niraparib) in China’s National Reimbursement Drug List

28 December 2020 - Zai Lab today announced that Zejula has been included in the updated National Reimbursement Drug List released ...

Read more →

BeiGene announces inclusion of three innovative oncology products in China National Reimbursement Drug List

27 December 2020 - Internally-developed anti-PD-1 antibody tislelizumab and BTK inhibitor Brukinsa (zanubrutinib) are included in the National Reimbursement Drug List ...

Read more →

Junshi Biosciences announces inclusion of toripalimab in the China National Reimbursement Drug List

29 December 2020 - Junshi Biosciences is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug ...

Read more →

BeiGene announces the approval in China of Blincyto (blinatumomab) for injection for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia

7 December 2020 - BeiGene today announced that the China NMPA has approved Blincyto (blinatumomab) for injection for the treatment of ...

Read more →

BeiGene announces the approval of Xgeva (denosumab) in China for the prevention of skeletal-related events in patients with bone metastases from solid tumours and in patients with multiple myeloma

19 November 2020 - BeiGene today announced that the China NMPA has approved Xgeva (denosumab) for the prevention of skeletal-related events ...

Read more →